OncLiveDr. McDermott on Novel Immunotherapy Combinations in RCCOncLiveDavid F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic rena… Continue reading
Madison.com |
Why IBM, GNC Holdings, and Intrexon Slumped Today
Motley Fool The synthetic biology specialist announced that it had closed its secondary offering of stock to investors, selling 6.9 million shares of common stock at $12.50 per share. That price was more than 12% below the stock’s price as of Thursday evening … ValuEngine Lowers Intrexon (XON) to Strong SellThe Lincolnian Online Somewhat Positive News Coverage Somewhat Unlikely to Affect Intrexon (XON) Stock PriceStockNewsTimes |
|
Young Boy Becomes First DMD Patient to Receive Investigational Systemic Microdystrophin Gene Therapy
Muscular Dystrophy News The first Duchenne muscular dystrophy (DMD) patient has received systemic microdystrophin gene therapy as part of a Phase 1/2 clinical trial at Nationwide Children’s Hospital in Columbus, Ohio. The trial (NCT03375164), currently recruiting participants … |
|
Protein designed entirely from scratch functions in cells as a genuine enzyme
Science Daily Researchers are on the cusp of a true synthetic biology, Hecht said. “E. coli has 4,000 different genes,” he said. “We didn’t test all 4,000, because the only way this experiment works is if nothing grows on minimal medium, and of the 4,000, that’s … |